Time magazine admitted HER2DXAnd Trial that indicates best treatment for breast cancer patientsas One of the best inventions of 2022,
Developed by Spanish biotechnological start-up Reveal Genomics, specializing in precision oncology through innovation in biomarkers, it has been included in the list of “Best Inventions of 2022” in the category “Medical Care”, which are used in medicine. There are innovations. consultations and hospitals and those who provide effective feedback to patients.
The list, compiled by Time each year and made public this Thursday, includes inventions that the publication defines as “makes the world better, smarter, and more fun”.
On HER2DX, Time has highlighted that “Supports better outcomes for early-stage patients, but may also lead to a more personalized approach to advanced-stage breast cancer.”,
For Dr. Patricia Villagrassa, Co-Founder and CEO of Reveal Genomics, this recognition “motivates us to continue with our vision of the future of precision oncology. We have set out to develop unique solutions with proven clinical utility.” company, and this thesis exemplifies our potential. Our immediate goal is to make sure HER2DX is available globally and reaches all HER2+ breast cancer patients.”
,HER2+ breast cancer is a health problem that affects more than 400,000 women a year, To date, we have no tools to help the oncologist and patient make important medical decisions for his or her life.
As a result, many patients experienced overtreatment or undertreatment. For this reason we developed HER2DX®, the first test to help optimize treatment for this type of patient”, explained Doctor. Alex Pratt, Co-Founder and CSO of Reveal Genomics.
best inventions of the year
This year, TIME recognized inventions that have reached critical milestones between November 2021 and September 2022, as in the case of HER2DX, which was introduced to market in January this year.
To create the list, TIME solicits nominations from its editors and reporters around the world, and also enables online nominations. Once the application is compiled, the publication evaluates each invention in aspects such as Impact, originality, creativity and effectiveness,
The full list of honorees appears in the print publication and on Time’s website (with a global audience of 100 million people), as well as the publication’s social media channels including Twitter (18 million followers), Facebook (13 million fans) and Instagram. . (11 million followers) and generates an estimated 650 million media impressions worldwide.
The world’s first clinical trial designed specifically for HER2+ breast cancer. Marketed by Reveal Genomics since January 2022, it is a P. IsStandardized expression test of 27 genes for patients with early-stage HER2+ breast cancer,
Provides a prognostic and predictive report based on clinical and genomic data. The test integrates clinical information (tumor size and node status) with biological information (immune infiltration, luminal differentiation, tumor cell proliferation, and expression of the HER2 chromosome amplicon 17q12-21 including the ERBB2 gene).